Next-IO™ Anti-GPRC5D × CD3 Therapeutic Bispecific Antibody Program

About This Program

This program aims to develop anti-GPRC5D × CD3 therapeutic Bispecific Antibody for immuno-oncology.

Rationale when developing the program:

For the reasons mentioned above, we propose a novel combination of GPRC5D / CD3 therapeutic BiTE, for which we believe will provide insights for the next generation of MM treatment.

GPRC5D

The G protein-coupled receptor family C group 5 member D (GPRC5D) is an orphan receptor consisting of seven-transmembrane proteins. It is expressed at very low levels in normal tissues, but high mRNA expression is observed in patients with MM. Furthermore, high expression of GPRC5D is linked to poor overall survival and genetic changes.

On the whole, these attributes of GPRC5D make it becomes a potential target for T cell-redirecting antibody (TRAB) therapy.

GPRC5D × CD3 in Cancer Studies

Here are some published data about GPRC5D × CD3 serving as a potential target for cancer immunotherapy.

Ongoing Clinical Trials

Program Planning and Management

Creative Biolabs has extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Anti-GPRC5D × CD3 Therapeutic Bispecific Antibody Program

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-GPRC5D × CD3 therapeutic Bispecific Antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance theirs with more chance to succeed. Look forward to cooperating with you in the near future.

Reference

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.